Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer



Status:Active, not recruiting
Conditions:Lung Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/8/2019
Start Date:February 22, 2012

Use our guide to learn which trials are right for you!

Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

This randomized phase II trial studies how well positron emission tomography (PET)/computed
tomography (CT)-guided radiation therapy works compared to standard radiation therapy in
treating patients with stage III non-small cell lung cancer. Radiation therapy uses
high-energy x-rays to kill tumor cells. Using imaging procedures, such as PET and CT scans,
to guide the radiation therapy, may help doctors deliver higher doses directly to the tumor
and cause less damage to healthy tissue.

PRIMARY OBJECTIVES:

I. To determine whether tumor dose can be escalated to improve the freedom from
local-regional progression-free (LRPF) rate at 2 years when an individualized adaptive
radiation treatment (RT) plan is applied by the use of a fludeoxyglucose F 18 (FDG)-positron
emission tomography (PET)/computed tomography (CT) scan acquired during the course of
fractionated RT in patients with inoperable stage III non-small cell lung cancer (NSCLC).
(National Surgical Adjuvant Breast and Bowel Project [NSABP], Radiation Therapy Oncology
Group [RTOG], Gynecologic Oncology Group [GOG] [NRG] Oncology) II. To determine whether the
relative change in standard uptake value (SUV) peak from the baseline to the during-treatment
FDG-PET/CT, defined as (during-treatment SUVpeak - baseline SUVpeak)/baseline SUV peak x
100%, can predict the LRPF rate with a 2-year follow up. (Eastern Cooperative Oncology Group
[ECOG]-American College of Radiology Imaging Network [ACRIN])

SECONDARY OBJECTIVES:

I. To determine whether an individualized dose escalation improves overall survival (OS),
progression-free survival (PFS), lung cancer cause-specific survival, and delays time to
local-regional progression compared to a conventional RT plan. (NRG Oncology) II. To compare
the rate of severe (grade 3+ Common Terminology Criteria for Adverse Events [CTCAE], v. 4)
radiation-induced lung toxicity (RILT) defined as severe RILT pneumonitis or clinical
fibrosis. (NRG Oncology) III. To compare other severe adverse events, including grade 3+
(CTCAE, v. 4) esophagitis or grade 2 pericardial effusions, or any grade cardiac adverse
events related to chemoradiation between a PET/CT-guided adaptive approach and a conventional
RT plan. (NRG Oncology) IV. To evaluate the association of baseline 18F-fluoromisonidazole
(FMISO), a PET/CT imaging agent uptake (tumor-to-blood pool ratio) with LRPF (i.e., the
assessment of using baseline FMISO-PET uptake as a prognostic marker). (ECOG-ACRIN) V. To
determine if the relative change in SUVpeak from baseline to during-treatment FDG-PET/CT
and/or baseline FMISO uptake (tumor-to-blood pool ratio) predicts the differential benefit of
the adaptive therapy, i.e., the association of uptake parameters with LRPF rate depending on
the assigned treatment thus, assessing if these uptake parameters can be useful in guiding
therapies, i.e., predictive markers. (ECOG-ACRIN) VI. To determine if other PET-imaging
uptake parameters (SUV peak during-treatment for FDG-PET, maximum SUV, or relative change of
maximum SUVs from pre- to during-treatment FDG-PET/CT, change in metabolic tumor volume,
FMISO total hypoxic volume, FMISO tumor to mediastinum ratio, EORTC or University of
Michigan/Kong's response criteria) will predict OS, LRPF rate, and lung cancer cause-specific
(LCS) survival as well as to explore the optimal threshold for differentiating responders
from non-responders. (ECOG-ACRIN)

CORRELATIVE SCIENCE OBJECTIVES:

I. To study whether a model of combining current clinical and/or imaging factors with blood
markers, including osteopontin (OPN) [for hypoxia marker], carcinoembryonic antigen (CEA) and
cytokeratin fragment (CYFRA) 21-1 (for tumor burden), and interleukin (IL)-6 (inflammation)
will predict the 2-year LRPF rate and survival better than a current model using clinical
factors and radiation dose as well as imaging factors.

II. To determine/validate whether a model of combining mean lung dose (MLD), transforming
growth factor beta1 (TGF beta1) and IL-8 will improve the predictive accuracy for clinical
significant RILT better comparing to the current model of using MLD alone.

III. To explore, in a preliminary manner, whether proteomic and genomic markers in the blood
prior to and during the early course of treatment are associated with tumor response after
completion of treatment, LRPF rate, PFS, OS, and pattern of failure and treatment-related
adverse events, such as radiation pneumonitis, esophagitis, and pericardial effusion.
(exploratory)

OUTLINE:

Prior to treatment, patients undergo fludeoxyglucose F 18 (FDG) positron emission tomography
(PET) and computed tomography (CT) scans at baseline and periodically during study. A subset
of patients also undergo 18F-fluoromisonidazole PET/CT scan at baseline. Patients are
randomized to 1 of 2 treatment arms:

ARM I (standard chemoradiotherapy): Patients undergo radiotherapy once daily (QD) 5 days a
week for 30 fractions. Patients also receive paclitaxel intravenously (IV) over 1 hour and
carboplatin IV over 30 minutes once weekly for 6 weeks. Patients undergo FDG-PET/CT imaging
between fractions 18 and 19.

ARM II (experimental chemoradiotherapy): Patients undergo an individualized dose of
image-guided radiotherapy QD 5 days a week for 30 fractions and undergo 18 F FDG-PET/CT
between fractions 18 and 19. Based on the scan results, patients undergo individualized
adaptive radiotherapy for the final 9 fractions. Patients also receive paclitaxel and
carboplatin as in Arm I.

CONSOLIDATION CHEMOTHERAPY: Beginning 4-6 weeks after chemoradiotherapy, patients receive
paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats
every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1 month, every 3 months for
1 year, every 6 months for 2 years, and then annually for 2 years.

Inclusion Criteria:

- Patients must have FDG-avid (maximum SUV >= 4.0) (from PET scan of any date, any
scanner) and histologically or cytologically proven non-small cell lung cancer

- Patients must be clinical American Joint Committee on Cancer (AJCC) stage IIIA or IIIB
(AJCC, 7th ed.) with non-operable disease; non-operable disease will be determined by
a multi-disciplinary treatment team, involving evaluation by at least 1 thoracic
surgeon within 8 weeks prior to registration; Note: For patients who are clearly
nonresectable, the case can be determined by the treating radiation oncologist and a
medical oncologist, or pulmonologist

- Patients with multiple, ipsilateral pulmonary nodules (T3 or T4) are eligible if a
definitive course of daily fractionated radiation therapy (RT) is planned

- History/physical examination, including documentation of weight, within 2 weeks prior
to registration

- FDG-PET/CT scan for staging and RT plan within 4 weeks prior to registration

- CT scan or sim CT of chest and upper abdomen (IV contrast is recommended unless
medically contraindicated) within 6 weeks prior to registration

- CT scan of the brain (contrast is recommended unless medically contraindicated) or MRI
of the brain within 6 weeks prior to registration

- Pulmonary function tests, including diffusion capacity of carbon monoxide (DLCO),
within 6 weeks prior to registration; patients must have forced expiratory volume in 1
second (FEV1) >= 1.2 Liter or >= 50% predicted without bronchodilator

- Zubrod performance status 0-1

- Able to tolerate PET/CT imaging required to be performed at an American College of
Radiology (ACR) Imaging Core Laboratory (Lab) qualified facility

- Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (within 2 weeks prior to
registration on study)

- Platelets >= 100,000 cells/mm^3 (within 2 weeks prior to registration on study)

- Hemoglobin (Hgb) >= 10.0 g/dL (note: the use of transfusion or other intervention to
achieve Hgb >= 10.0 g/dL is acceptable) (within 2 weeks prior to registration on
study)

- Serum creatinine within normal institutional limits or a creatinine clearance >= 60
ml/min within 2 weeks prior to registration

- Negative serum or urine pregnancy test within 3 days prior to registration for women
of childbearing potential

- Women of childbearing potential and male participants must agree to use a medically
effective means of birth control throughout their participation in the treatment phase
of the study

- The patient must provide study-specific informed consent prior to study entry

Exclusion Criteria:

- Patients with any component of small cell lung carcinoma are excluded

- Patients with evidence of a malignant pleural or pericardial effusion are excluded

- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity,
or cervix are all permissible)

- Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
different cancer is allowable

- Prior radiotherapy to the region of the study cancer that would result in overlap of
radiation therapy fields

- Severe, active co-morbidity, defined as follows:

- Unstable angina and/or congestive heart failure requiring hospitalization within
the last 6 months

- Transmural myocardial infarction within the last 6 months

- Acute bacterial or fungal infection requiring intravenous antibiotics at the time
of registration

- Chronic obstructive pulmonary disease exacerbation or other respiratory illness
requiring hospitalization or precluding study therapy at the time of registration

- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects;
note, however, that laboratory tests for liver function and coagulation
parameters are not required for entry into this protocol

- Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease
Control (CDC) definition; note, however, that human immunodeficiency virus (HIV)
testing is not required for entry into this protocol

- Pregnancy or women of childbearing potential and men who are sexually active and not
willing/able to use medically acceptable forms of contraception

- Poorly controlled diabetes (defined as fasting glucose level > 200 mg/dL) despite
attempts to improve glucose control by fasting duration and adjustment of medications;
patients with diabetes will preferably be scheduled in the morning and instructions
for fasting and use of medications will be provided in consultation with the patients'
primary physicians

- Patients with T4 disease with radiographic evidence of massive invasion of a large
pulmonary artery and tumor causing significant narrowing and destruction of that
artery are excluded
We found this trial at
30
sites
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Daphna Y. Gelblum
Phone: 212-639-5007
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Jennifer T. Eubanks
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Shruti Jolly
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Augusta, Georgia 30912
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-1663
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Basking Ridge, New Jersey 07920
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: James G. Ravenel
Phone: 843-792-9321
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Gaurav Marwaha
Phone: 312-942-5498
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Principal Investigator: Mitchell Machtay
Phone: 800-641-2422
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
216.476.7000
Principal Investigator: Mitchell Machtay
Phone: 800-641-2422
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Mitchell Machtay
Phone: 800-641-2422
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Commack, New York 11725
?
mi
from
Commack, NY
Click here to add this to my saved trials
500 Westchester Avenue
Harrison, New York 10604
?
mi
from
Harrison, NY
Click here to add this to my saved trials
Independence, Ohio 44131
Principal Investigator: Gregory M. M. Videtic
Phone: 866-223-8100
?
mi
from
Independence, OH
Click here to add this to my saved trials
535 Barnhill Dr
Indianapolis, Indiana 46202
(888) 600-4822
Principal Investigator: Timothy Lautenschlaeger
Phone: 317-274-2552
Indiana University Melvin and Bren Simon Cancer Center At the IU Simon Cancer Center, more...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
4401 Wornall Rd
Kansas City, Missouri 64111
(816) 932-2000
Principal Investigator: Rakesh Gaur
Phone: 913-948-5588
Saint Luke's Hospital, Kansas City Saint Luke's Hospital is a not-for-profit tertiary referral center committed...
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Louisville, Kentucky 40202
Principal Investigator: Neal E. Dunlap
Phone: 866-530-5516
?
mi
from
Louisville, KY
Click here to add this to my saved trials
600 Highland Ave
Madison, Wisconsin 53792
(608) 263-6400
Principal Investigator: Andrew M. Baschnagel
Phone: 715-422-7718
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
?
mi
from
Madison, WI
Click here to add this to my saved trials
Mayfield Heights, Ohio 44124
Principal Investigator: Mitchell Machtay
Phone: 800-641-2422
?
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
9200 W Wisconsin Ave
Milwaukee, Wisconsin 53226
(414) 805-3666
Principal Investigator: Elizabeth M. Gore
Phone: 414-805-4380
Froedtert and the Medical College of Wisconsin Froedtert Health combines with the Medical College of...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Montreal, Quebec
Principal Investigator: Sergio L. Faria
Phone: 514-934-4400
?
mi
from
Montreal,
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
Principal Investigator: Terence S. Herman
Phone: 405-271-8777
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
875 Blake Wilbur Drive
Palo Alto, California 94304
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
Principal Investigator: Mark A. Hallman
Phone: 215-728-4790
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
3401 N Broad St
Philadelphia, Pennsylvania
(215) 707-2000
Principal Investigator: Vladimir Valakh
Phone: 215-728-2983
Temple University Hospital On January 18, 1892 a three-story house at 3403 North Broad Street...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rockville Centre, New York 11570
?
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Jeffrey D. Bradley
Phone: 800-600-3606
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
777 Broadway
Sleepy Hollow, New York 10591
?
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Strongsville, Ohio 44136
Principal Investigator: Mitchell Machtay
Phone: 800-641-2422
?
mi
from
Strongsville, OH
Click here to add this to my saved trials
300 South 6th Avenue
West Reading, Pennsylvania 19611
(610) 988-8000
Reading Hospital At Reading Health System, advancing your health and wellness is our mission. When...
?
mi
from
West Reading, PA
Click here to add this to my saved trials
Wooster, Ohio 44691
Principal Investigator: Mitchell Machtay
Phone: 800-641-2422
?
mi
from
Wooster, OH
Click here to add this to my saved trials